Clinical trials: Hepatitis C, completed
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02378935
- Testing
- VOX, SOF/VEL, RBV
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 205 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche…
- Trial name
- NCT00800735
- Testing
- Pegylated-interferon alfa-2a, Ribavirin
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Hepatitis B
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.
- Conditions
- Hepatitis C, Hepatitis B, Liver Cirrhoses
- Trial name
- NCT03620474
- Testing
- PRI-724
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Kiminori Kimura, MD
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected participants who will be randomized to receive…
- Trial name
- NCT01329913
- Testing
- MK-6325
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Breast Cancer
Hepatitis C Screening Paired With Mammography
In France, a breast cancer screening is organized since 2004 for women aged 50-74. On the other hand, even though the seroprevalence of hepatitis C in the general French population is less than 1%, it is estimated that more than…
- Trial name
- Mammo'C (NCT05067374)
- Where
- 4 sites in France
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
HIV Infections, Hepatitis C
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The purpose of this study is to investigate the immune responses to two different vaccine formulations in HIV-infected, HCV-infected, and…
- Trial name
- NCT00393276
- Testing
- Twinrix, Decavac
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Phase I Trial of Silymarin for Chronic Liver Diseases
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
- Trial name
- SyNCH (NCT00389376)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Hepatitis C
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
The main purpose of this study is to determine the safety and tolerability of multiple dosing of miravirsen in subjects infected with chronic hepatitis C.
- Trial name
- NCT01200420
- Testing
- miravirsen, saline
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Chronic
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g.
- Trial name
- NCT01447446
- Testing
- Peg-IFN Alfa-2a, Peg-IFN Alfa-2b, Ribavirin
- Where
- 271 sites in Belgium, Egypt and 25 more
- Volunteers
- 4,442 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China
The primary objective of this study is to estimate the distributions of HCV viral/human genotypes (including IL28B and inosine triphosphatase, ITPA), and HCV RNA level among ITPA gene among 1000 Han ethnic Chinese patients with…
- Trial name
- HCV (NCT01293279)
- Where
- China
- Volunteers
- 997 people
- Sponsor
- Peking University People's Hospital
Hepatitis C Virus-infected Cirrhosis
An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis
The purpose of this study is to investigate the safety and tolerability of PRI-724 in patients with HCV-induced cirrhosis.
- Trial name
- NCT02195440
- Testing
- PRI-724
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Komagome Hospital
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than…
- Trial name
- HEPCAT (NCT01125189)
- Testing
- Daclatasvir, peg-interferon alfa-2a, ribavirin
- Where
- 64 sites in United States, Australia and 9 more
- Volunteers
- 558 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Ribavirin Dose Optimization for the Treatment of Hepatitis C
Patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a category of patients for whom there is currently no worthwhile therapeutic alternative.
- Trial name
- NCT01289496
- Testing
- Peg-interferon alpha-2a, Ribavirin
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatitis C, Chronic
Evaluation of Dried Blood Spot for HCV RNA Testing
FIND is preparing a study to evaluate the performance, as measured by sensitivity and specificity, of four centralized assays for the detection of HCV RNA using capillary blood collected on dried blood spots (DBS) and plasma…
- Trial name
- NCT03896087
- Testing
- Abbott RealTime HCV assay from DBS, HCV for use on the cobas® 6800/8800 Systems from PSC and DBS, Aptima® HCV Quant Dx Assay from DBS
- Where
- 5 sites in Australia, Cameroon and 3 more
- Volunteers
- 942 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Hepatitis C Virus
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
- Trial name
- NCT01257204
- Testing
- Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
Hepatitis C
Surveillance and Treatment of Prisoners With Hepatitis C
The purpose of the study is to assess how feasible it is to treat and prevent the transmission of Hepatitis C in the prison setting to achieve substantial reductions in the incidence and prevalence of Hepatitis C.
- Trial name
- SToP-C (NCT02064049)
- Testing
- Sofosbuvir/velpatasvir
- Where
- 4 sites in Australia
- Volunteers
- 3,692 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.